Clinical Trials Directory

Trials / Unknown

UnknownNCT02323841

Feasibility Study: Conservative Treatment in Cervical Cancer

Feasibility Study: Conservative Treatment in Cervical Cancer FIGO Stage IB1-IIA1 > 2cm

Status
Unknown
Phase
EARLY_Phase 1
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
Catholic University of the Sacred Heart · Academic / Other
Sex
Female
Age
18 Years – 40 Years
Healthy volunteers
Not accepted

Summary

Currently conservative treatment for patients of childbearing affected by cervical cancer is reserved for women with FIGO stage IA2 - IB1 with tumor size less than 2 cm . The trachelectomy and the cone biopsy with pelvic lymphadenectomy are the choice for these patients wishing to preserve their reproductive function. In this context , recently literature show the results about the use of neo-adjuvant chemotherapy about the reduction of tumor volume and therefore the magnitude of the subsequent surgical treatment (including patients with tumors larger than 2 cm ). So it becomes crucial a prospective analysis on the possibility to include in this type of treatment patients with stage IB1 and IIA1 with tumor size greater than 2 cm ( up to 4 cm ) . The current study , in fact , would like to do a prospective evaluation on the advantages of neo-adjuvant chemotherapy in the possibility of broadening the inclusion criteria to conservative treatment in women , suffering from cervical cancer, stage IB1 and IIA1 ( with tumor volume between 2 and 4 cm) and wishing to preserve their reproductive function.

Detailed description

The investigators would like to be conservative in young patients affected by early stage cervical cancer.

Conditions

Interventions

TypeNameDescription
PROCEDUREconservative treatmentwe performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments

Timeline

Start date
2014-03-01
Primary completion
2014-03-01
Completion
2015-03-01
First posted
2014-12-24
Last updated
2014-12-24

Locations

1 site across 1 country: Italy

Source: ClinicalTrials.gov record NCT02323841. Inclusion in this directory is not an endorsement.